PubRank

S Bunting

Author PubWeight™ 113.66‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976 13.19
2 Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 1976 4.54
3 Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 1976 4.44
4 Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 1977 3.80
5 The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976 3.63
6 Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther 1990 3.55
7 Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994 3.11
8 Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 1976 2.83
9 A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 2001 2.77
10 Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins 1977 2.48
11 A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 1976 2.28
12 Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995 2.07
13 The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol 1976 2.06
14 Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995 1.92
15 Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001 1.64
16 Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996 1.63
17 Prostacyclin is a circulating hormone. Nature 1978 1.60
18 Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins 1976 1.56
19 Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci U S A 1990 1.55
20 Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation 1995 1.51
21 Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991 1.44
22 Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins 1976 1.40
23 The regulation of blood vessel growth by vascular endothelial growth factor. Ann N Y Acad Sci 1995 1.34
24 Effects of intravenous infusion of prostacyclin (PGI2) in man. Prostaglandins 1980 1.30
25 Inhibition of phospholipase C dependent processes by U-73, 122. Adv Prostaglandin Thromboxane Leukot Res 1989 1.27
26 Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol 1994 1.22
27 Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994 1.21
28 Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997 1.21
29 The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull 1983 1.20
30 A monoclonal antibody that inhibits mouse tissue factor function. J Thromb Haemost 2005 1.19
31 Metabolism of leukotriene A4 by human erythrocytes. A novel cellular source of leukotriene B4. J Biol Chem 1984 1.18
32 Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man. Br J Clin Pharmacol 1979 1.16
33 Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol 1996 1.14
34 Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 1996 1.12
35 Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992 1.10
36 Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature 1985 1.09
37 Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995 1.08
38 Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 1999 1.02
39 Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection. J Pharmacol Exp Ther 1998 1.01
40 VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998 0.99
41 Voices and paradigms: perspectives on critical and feminist theory in nursing. ANS Adv Nurs Sci 1991 0.98
42 Antithrombotic properties of vascular endothelium. Lancet 1977 0.98
43 Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001 0.97
44 Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995 0.92
45 Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest 1995 0.91
46 Evidence that S-nitrosothiols are responsible for the smooth muscle relaxing activity of the bovine retractor penis inhibitory factor. J Pharmacol Exp Ther 1992 0.91
47 Peripheral vascular stenosis in apolipoprotein E-deficient mice. Potential roles of lipid deposition, medial atrophy, and adventitial inflammation. Arterioscler Thromb Vasc Biol 1997 0.90
48 Proceedings: Formation of prostaglandin endoperoxides and rabbit aorta contracting substance (RCS) by coupling two enzyme systems. Br J Pharmacol 1976 0.90
49 Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol 1997 0.89
50 Prostacyclin: a solution to some problems of extracorporeal circulation. Experiments in greyhounds. Lancet 1979 0.89
51 Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995 0.88
52 Dobutamine stress cine-MRI of cardiac function in the hearts of adult cardiomyocyte-specific VEGF knockout mice. J Magn Reson Imaging 2001 0.86
53 Prostacyclin in physiology and pathophysiology. Int Rev Exp Pathol 1982 0.86
54 Prostacyclin can replace heparin in haemodialysis in dogs. Lancet 1978 0.85
55 Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996 0.84
56 Resting blood pressure and thermal pain responses among females: effects on pain unpleasantness but not pain intensity. Int J Psychophysiol 1998 0.83
57 Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J Cardiovasc Pharmacol 1996 0.82
58 A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997 0.81
59 Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats. J Pharmacol Exp Ther 2001 0.81
60 Leukotriene B4 and 20-hydroxyleukotriene B4 contract guinea-pig trachea strips in vitro. J Pharmacol Exp Ther 1986 0.81
61 Generation of thromboxane A2-like activity from prostaglandin endoperoxides by polymorphonuclear leukocyte homogenates [proceedings]. Br J Pharmacol 1976 0.81
62 Inhibition of platelet activation by prostacyclin: possible consequences in coagulation and anticoagulation. Thromb Res 1981 0.80
63 G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs. Thromb Haemost 1992 0.79
64 Effects of gender and acute dental pain on thermal pain responses. Clin J Pain 1999 0.79
65 In vivo characterization of synthetic thromboxane A2 in canine myocardium. Circ Res 1987 0.79
66 Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. Blood 1992 0.79
67 Effect of selective or combined inhibition of integrins alpha(IIb)beta(3) and alpha(v)beta(3) on thrombosis and neointima after oversized porcine coronary angioplasty. Circulation 2001 0.78
68 Effects of VEGF on hemodynamics and cardiac function: characterization and mechanisms. IDrugs 2000 0.78
69 Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharmacol 1997 0.77
70 Pressor and bradycardic effects of centrally administered relaxin in conscious rats. Am J Hypertens 1995 0.77
71 Peripheral neuropathy in patients with HIV infection: consider dual pathology. Sex Transm Infect 2002 0.76
72 Pulmonary pharmacology of synthetic thromboxane A2. Adv Prostaglandin Thromboxane Leukot Res 1987 0.75
73 Antithrombotic drugs in relation to prostaglandin metabolism. Clin Haematol 1980 0.75
74 An antiserum to 5,6-dihydro prostacyclin (PGI1) which also binds prostacyclin. Prostaglandins 1978 0.75
75 Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994 0.75
76 Comparison of VEGF delivery techniques on collateral-dependent microvascular reactivity. Microvasc Res 1998 0.75
77 Support for the terminally ill: letting conscience by the guide. Volunt Leader 1983 0.75
78 RGD-containing peptides inhibit adhesion of 293 cells transfected with GpIIb/IIIa to fibrinogen: comparison to inhibition of platelet aggregation. Blood Coagul Fibrinolysis 1993 0.75
79 Triangulation research among culturally diverse populations. J Allied Health 2000 0.75
80 The effect of cyclo-oxygenase and thromboxane synthetase inhibitors on shock induced by injection of heterologous blood in cats. Thromb Res 1983 0.75
81 Effects of growth hormone in rats with postinfarction left ventricular dysfunction. Cardiovasc Drugs Ther 1995 0.75
82 Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Thromb Haemost 1998 0.75
83 Prostacyclin eliminates the thrombocytopenia associated with charcoal hemoperfusion and minimizes heparin and fibrinogen consumption. Artif Organs 1980 0.75
84 Ethical decision making by nurses in HIV/AIDS situations. J Assoc Nurses AIDS Care 1992 0.75
85 An experimental model of intracranial hemorrhage during thrombolytic therapy with t-PA. Thromb Haemost 1996 0.75
86 [Clinical study of prostacyclin in extracorporeal circulation. Effects on hemodynamics and coagulation]. Arch Mal Coeur Vaiss 1982 0.75
87 Electrophoretic study of genetic variation in British Myzus persicae (Sulz.) (Hemiptera, Aphididae). Biochem Genet 1978 0.75
88 Haemodialysis without heparin. Proc Eur Dial Transplant Assoc 1978 0.75
89 Prostacyclin eliminates the bioincompatibility of charcoal haemoperfusion. Proc Eur Dial Transplant Assoc 1979 0.75
90 Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arterioscler Thromb 1993 0.75